Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 17/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 12/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 10/20 | 0.57 |
| ▸ | FAP | Q12884 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 6/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774998 | 1.00 | DPP8 (0.57) | DPP8DPP7DPP9FAPDPP4 | |
| SCHEMBL14027807 | 0.87 | HDAC8 (0.59) | DPP8DPP7DPP9DPP4HDAC8 | |
| SCHEMBL14102622 | 0.87 | HDAC8 (0.59) | DPP8DPP7DPP9DPP4HDAC8 | |
| Hydrochloric Acid SCHEMBL4940326 | 0.85 | HDAC8 (0.60) | DPP8DPP7DPP9DPP4HDAC8 | |
| Hydrochloric Acid SCHEMBL4940337 | 0.85 | HDAC8 (0.60) | DPP8DPP7DPP9DPP4HDAC8 | |
| SCHEMBL4772391 | 0.84 | HDAC8 (0.54) | DPP8DPP7DPP9DPP4HDAC8 | |
| SCHEMBL4911736 | 0.81 | HDAC8 (0.52) | DPP8DPP7DPP9FAPHDAC8 | |
| SCHEMBL4776668 | 0.81 | HDAC8 (0.52) | DPP8DPP7DPP9FAPHDAC8 | |
| SCHEMBL21159095 | 0.78 | SMN1; SMN2 (0.48) | DPP8DPP7DPP9FAPDPP4 | |
| SCHEMBL14359644 | 0.75 | DPP4 (0.46) | DPP8DPP7DPP9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | DPP8 1164/4885DPP7 921/4885DPP9 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.